Alembic Pharmaceuticals has reported results for second quarter ended September 30, 2015.
The company has over three fold jump in its net profit after tax at Rs 252.67 crore for the quarter ended September 30, 2015 as compared to Rs 84.05 crore for the same quarter in the previous year. The company’s total income has increased by 70.37% to Rs 922.59 crore for the quarter under review from Rs 541.52 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported over three fold jump in its net profit/(loss) after tax and share of profit of associates at Rs 288.90 crore for the quarter ended September 30, 2015 as compared to Rs 77.27 crore for the same quarter in the previous year. Total income of the company has increased by 84.35% at Rs 1008.81 crore for quarter under review as compared to Rs 547.22 crore for the quarter ended September 30, 2014.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.50 |
| Dr. Reddys Lab | 1221.45 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 930.90 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: